Additional studies are needed to elucidate the efficacy and safety of CD38-targeted therapies, such as bispecific antibodies, trispecific antibodies, ADCs, multitarget CARTs, and CAR-NK cell therapy, in acute leukemia. Here, CD38 is linked to acute leukemia.